Literature DB >> 29296312

Bilateral malignant metastases to the internal auditory canal: radiosurgical management.

Marcos Dellaretti1, Eduardo K Tagawa2,3, Julio Leonardo Barbosa Pereira4, Mariana Pedrini2,3, Baltazar Leão Reis4, Atos Alves de Sousa1.   

Abstract

Malignant melanomas constitute 1-8% of all malignant tumors and are the third most common tumor to metastasize to the central nervous system. However, metastases to the cerebellopontine angle (CPA) are rare, accounting for only 0.2 to 0.7% of the lesions identified in this location Case Report. A 62-year-old white man with a history of melanoma of the back, who had had all lesions completely excised, was reportedly tumor-free for 6 years. The patient presented bilateral metastatic CPA melanoma. Left side tumor was treated with surgery with partial resection (lost hearing) and radisorugery. Right side lesion was treated with radiosurgery and hearing preserved for 8 months, tumor controlled for 12 months, until death due to leptomeningeal carcinomatosis after 13 months of radiosurgey. The patient underwent intensity-modulated stereotactic radiosurgery using BrainLab Iplan 4.1 for both IAC lesions, the dose was 18Gy prescribed to the 80% isodose line delivered by 11 fields. The patient presented no post-radiosurgery neurological complications.
Conclusion: In patients with lesions in the CPA, a diagnosis of melanoma should be included, particularly in cases with rapid progression of symptoms. Therefore, radiosurgery is a viable treatment option since the hearing can be preserved and tumor control achieved.

Entities:  

Keywords:  Malignant melanoma; metastases; stereotactic radiosurgery

Year:  2011        PMID: 29296312      PMCID: PMC5675475     

Source DB:  PubMed          Journal:  J Radiosurg SBRT


  10 in total

1.  Melanoma metastasis masquerading as bilateral acoustic neuromas.

Authors:  Walter T Lee; Peter C Weber
Journal:  Otolaryngol Head Neck Surg       Date:  2005-03       Impact factor: 3.497

2.  Integration of gamma knife surgery in the management of cerebral metastases from melanoma.

Authors:  Athena Christopoulou; Spyros Retsas; Derek Kingsley; Ian Paddick; Christer Lindquist
Journal:  Melanoma Res       Date:  2006-02       Impact factor: 3.599

3.  Bilateral metastases in the cerebellopontine angle.

Authors:  O Delerue; A Destee; P Devos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-06       Impact factor: 10.154

4.  Primary malignant melanoma of the cerebellopontine angle: a diagnostic dilemma: case report.

Authors:  Chima O Oluigbo; Stephen R Cooke; Peter A Flynn; Kishor A Choudhari
Journal:  Neurosurgery       Date:  2006-12       Impact factor: 4.654

5.  Choroidal melanoma metastasis as a rare cause of cerebellopontine angle lesion: 2 case reports.

Authors:  R van Wiltenburg; R J Sevick; A W Clark; P C Burger; F E LeBlanc
Journal:  Can Assoc Radiol J       Date:  1998-06       Impact factor: 2.248

6.  Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome.

Authors:  I E Panagiotou; E N Brountzos; D A Kelekis; M A Papathanasiou; D I Bafaloukos
Journal:  Neoplasma       Date:  2005       Impact factor: 2.575

7.  Unusual lesions of the cerebellopontine angle: a segmental approach.

Authors:  F Bonneville; J L Sarrazin; K Marsot-Dupuch; C Iffenecker; Y S Cordoliani; D Doyon; J F Bonneville
Journal:  Radiographics       Date:  2001 Mar-Apr       Impact factor: 5.333

Review 8.  Metastatic melanoma to the cerebellopontine angle. Clinical and imaging characteristics.

Authors:  M A Arriaga; W W Lo; D E Brackmann
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1995-09

Review 9.  Bilateral malignant melanoma metastases to the internal auditory canal/cerebellopontine angle: surgical management and preservation of function.

Authors:  Venelin M Gerganov; Nirjhar Hore; Christian Herold; Karsten Wrede; Alexandru C Stan; Amir Samii; Madjid Samii
Journal:  J Neurosurg       Date:  2008-04       Impact factor: 5.115

10.  CPA melanoma: diagnosis and management.

Authors:  Derald E Brackmann; Joni K Doherty
Journal:  Otol Neurotol       Date:  2007-06       Impact factor: 2.311

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.